Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GI267119 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GI267119 | EXPERIMENTAL | 25 mg ODT tablet strength |
| Name | Type | Description |
|---|---|---|
| Lamotrigine | DRUG | Lamotrigine |
| GI267119 | DRUG | 25 mg ODT |
Inclusion Criteria: * Body weight \>50 kg (males) or \>45 kg (females) and BMI within the range 19 to 30 kg/m2 inclusive. Exclusion Criteria: * Female subjects of childbearing potential will not be eligible to participate if they are unwilling or unable to use an appropriate method of contracepti...
GI267119 is an investigational small molecule being developed for mental disorders. It is in Phase 1 clinical development, meaning it is still being studied in early-stage trials and has not been approved for any use. The drug is being evaluated for its safety and tolerability in healthy volunteers.
GI267119 is being developed by GSK plc, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol GSK. The company is conducting clinical research on this investigational small molecule for the treatment of mental disorders.
GI267119 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing early-stage clinical trials to assess its safety and tolerability in humans.
GI267119 has been studied in one completed Phase 1 clinical trial, identified as NCT00410371. This trial, titled 'Study to Compare Two Formulations of Lamotrigine in Healthy Subjects,' enrolled 96 participants in the United States and was a randomized, uncontrolled study in healthy volunteers aged 19 years and older.
GI267119 is an investigational drug being studied in a clinical trial that compares two formulations of lamotrigine, a medication used for mental disorders. The trial is designed to evaluate the pharmacokinetics of these formulations, and GI267119 is the investigational product being tested in this context.